Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

NCT ID: NCT01273948

Last Updated: 2012-02-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 66 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2012-02-29

Brief Summary

This will be a randomized, open-label, active-control Phase II pilot trial of bavituximab combined with ribavirin for initial treatment of chronic HCV genotype 1 infection. Eligible patients with normal coagulation, hematological, and renal function will undergo a screening/washout period of up to 28 days, followed by randomization to receive weekly bavituximab or PEG-IFN alpha-2a therapy for 12 weeks, both with twice-daily ribavirin.

The primary endpoint of this study is the proportion of patients who show a greater than or equal to 2-log10 IU reduction in plasma HCV RNA level after 12 weeks of treatment (early virological response; EVR).

Secondary endpoints include the proportion of patients with an undetectable HCV RNA level after 12 weeks of treatment; the proportion of patients who show a reduction in HCV RNA level of greater than or equal to 2 log10 IU after 4 weeks of treatment, viral kinetics for individual patients over time, and comprehensive evaluation of the safety and tolerability of bavituximab infusion.

Detailed Description

Primary Objective: The primary objective of this study is to assess the effect of 12 weeks of initial treatment with bavituximab versus PEG-IFN, each combined with ribavirin, on plasma HCV RNA level in patients with chronic HCV genotype 1 infection.

Conditions

Hepatitis C

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Bavituximab 3 mg/kg

Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks

Group Type: EXPERIMENTAL

Bavituximab

Intervention Type: DRUG

1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

Bavituximab 0.3 mg/kg

Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks

Group Type: EXPERIMENTAL

Bavituximab

Intervention Type: DRUG

1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

Pegylated interferon (PEG-IFN)

Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks

Group Type: ACTIVE_COMPARATOR

Pegylated interferon (PEG-IFN)

Intervention Type: DRUG

Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks

Interventions

Bavituximab

1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or

Intervention Type: DRUG

Pegylated interferon (PEG-IFN)

Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks

Intervention Type: DRUG

Other Intervention Names

Bavituxmab; Pegasys

Eligibility Criteria

Inclusion Criteria

1. Male or female between the ages of 18 and 65 years

2. Chronic hepatitis C virus (HCV) genotype 1 infection

3. HCV RNA level >10,000 IU/mL

4. Chronic HCV infection, defined as:

• Previous documentation of positive HCV serology (HCV antibody or RNA) at least 6 months (24 weeks) previously, or
• Positive HCV serology (HCV antibody or RNA) with a prior remote (more than 6 months previously) risk factor for acquisition of HCV or
• Historical biopsy consistent with chronic HCV infection

5. No clinically significant abnormalities in hematology, coagulation, or chemistry variables:

• Hemoglobin >12 g/dL for women; >13 g/dL for men
• Total white cell count >3000/mm3 and absolute neutrophil count >1500/mm3
• Platelets >100,000/mm3
• Prothrombin time (PT) and/or international normalized ratio (INR) less than or equal to 1.2 times the local upper limit of normal (ULN)
• Conjugated (direct) bilirubin less than or equal to 1.5 times the ULN
• Serum creatinine within normal limits
• Thyroid-stimulating hormone (TSH) and free thyroxine (T4) within normal limits

6. Female patients: negative urine pregnancy test

7. Ability to provide informed consent

Exclusion Criteria

1. Previous interferon-based antiviral therapy for chronic HCV infection

2. Previous treatment with known immunogenic drugs

3. Concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection

4. Cause of liver disease other than chronic HCV infection, such as autoimmune or alcoholic liver disease

5. Decompensated clinical liver disease, including a history of encephalopathy, bleeding esophageal or gastric varices, or ascites

6. Recipient of liver or other solid-organ transplantation

7. Evidence of clinically significant bleeding, defined as gross hematuria, hemoptysis, or gastrointestinal bleeding

8. History of bleeding diathesis or coagulopathy (eg, von Willebrand disease or hemophilia)

9. History of thromboembolic events (eg, deep-vein thrombosis [DVT] or pulmonary embolism). Previous central venous catheter-related thrombosis is acceptable if there is resolution recorded at least 12 months before enrollment.

10. Requirement for concurrent treatment with oral or parenteral anticoagulants or hormones (estrogen-containing contraceptives, hormone replacement, antiestrogen agents, progestins)

11. Condition requiring daily therapy with antiplatelet agents (eg, thienopyridines, dipyridamole, cilostazol; cardiovascular prophylaxis with aspirin is allowed) or corticosteroids

12. Investigational therapy within 28 days before the first planned dose of study drug

13. Major surgery within 28 days before the first planned dose of study drug

14. Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease)

15. Ongoing angina pectoris or other symptoms of coronary artery disease (CAD); history of stroke, or transient ischemic attack (TIA)

16. History of suicidal ideation or attempt

17. Condition requiring treatment (past or current) with coumarin-type agents

18. Cardiac arrhythmia requiring medical therapy

19. Serious nonhealing wound (including wound healing by secondary intention, ulcer, or bone fracture)

20. Cancer, autoimmune disease, or any disease or concurrent therapy known to cause significant alteration in immune function (corticosteroids are allowed before study enrollment and during the study to treat an AE)

21. Female patients and female partners of male patients: pregnancy, lactation, or inability/unwillingness to practice effective contraception

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peregrine Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janet Nuttall, MPH

Role: STUDY_CHAIR

Peregrine Pharmaceuticals

Locations

LTD Vakhtang Bochorishvili Anticeptic Centre

Tbilisi, , Georgia

Countries

Georgia

Other Identifiers

PPHM 1003

Identifier Type: -

Identifier Source: org_study_id